Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entinostat in Relapsed or Refractory Abdominal Neuroendocrine Tumors
NCT03211988Phase 2Terminated
- Start
- Dec 2017
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of entinostat in Neuroendocrine Neoplasm (NEN). Primary endpoint: Objective Response Rate at 44 months. Started Dec 2017; status: terminated.
02
Drugs
entinostat
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT03211988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03211988.